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Abstract
Background: We have been studying the native humoral immune response to cancer and have isolated a library of fully human
autoantibodies to a variety of malignancies. We previously described the isolation and characterization of two fully human
monoclonal antibodies, 27.F7 and 27.B1, from breast cancer patients that target the protein known as GIPC1, an accessory PDZ-
domain binding protein involved in regulation of G-protein signaling. Human monoclonal antibodies, 27.F7 and 27.B1, to GIPC1
demonstrate specific binding to malignant breast cancer tissue with no reactivity with normal breast tissue.
Methods: The current study employs cELISA, flow cytometry, Western blot analysis as well as immunocytochemistry, and
immunohistochemistry. Data is analyzed statistically with the Fisher one-tail and two-tail tests for two independent samples.
Results: By screening several other cancer cell lines with 27.F7 and 27.B1 we found consistently strong staining of other human
cancer cell lines including SKOV-3 (an ovarian cancer cell line). To further clarify the association of GIPC1 with breast and
ovarian cancer we carefully studied 27.F7 and 27.B1 using immunocytochemical and immunohistochemical techniques. An
immunohistochemical study of normal ovarian tissue, benign, borderline and malignant ovarian serous tumors, and different
types of breast cancer revealed high expression of GIPC1 protein in neoplastic cells. Interestingly, antibodies 27.F7 and 27.B1
demonstrate differential staining of borderline ovarian tumors. Examination of different types of breast cancer demonstrates
that the level of GIPC1 expression depends on tumor invasiveness and displays a higher expression than in benign tumors.
Conclusion: The present pilot study demonstrates that the GIPC1 protein is overexpressed in ovarian and breast cancer,
which may provide an important diagnostic and prognostic marker and will constitute the basis for further study of the role that
this protein plays in malignant diseases. In addition, this study suggests that human monoclonal antibodies 27.F7 and 27.B1 should
be further evaluated as potential diagnostic tools.
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We previously described the isolation and characteriza-
tion of a large panel of fully human monoclonal antibod-
ies from patients with breast cancer [1]. Many of these
antibodies are highly sensitive and specific for breast can-
cer and some also demonstrate high sensitivity and specif-
icity for non-autologous malignancies of different types.
The antigen target of two of these antibodies, 27.F7 and
27.B1 is the protein GIPC1, which is a member of a family
of PDZ-domain conserved proteins.
GIPC1 is a carboxy-terminal GAIP interacting protein and
together they are components of a G-protein-coupled sig-
naling complex thought to be involved in vesicular traf-
ficking. The PDZ domain of the GIPC family proteins
interacts with C terminal regions of FZD3, IGF1 receptor,
TrkA, TGF-β RIII, integrin α6A, 5T4 and RGS19 [2]. Thus
GIPC1, like other PDZ domain-containing proteins, may
function to cluster signaling molecules and membrane
receptors in specific membrane microdomains [3].
Because RGS19 is a member of the RGS family that regu-
lates heterotrimeric G-protein signaling, the GIPC1 family
of proteins might function as scaffolds linking heterot-
rimeric G-proteins to receptor tyrosine kinases.
It is also known that GIPC1 not only interacts with TGF-β
type III receptor (TGF-β RIII) [4], but also induces its
increased expression on the cell surface, leading to an
enhanced responsiveness to TGFβ. Down-regulation of
GIPC1 mRNA in tumors might promote cellular prolifer-
ation through interference of TGFβ signaling [5]. On the
other hand, Awan et.al. suggested a metastatic role for
GIPC1 protein demonstrating its close interaction with
5T4 protein, which has a great impact on the actin
cytoskeleton and cell migration [6]. In addition, GIPC1
was shown to interact with alpha-actinin-1 [7], which is
important for stabilizing actin bundles. It was also shown
to be involved with cell adhesion through its close link
with E-cadherin in epithelial cells [8]. Therefore, GIPC1
might play key roles in carcinogenesis and embryogenesis
through modulation of growth factor signaling
In our previous study antibodies 27.F7 and 27.B1 were
studied using immunofluorescence on breast cancer spec-
imens. They were highly specific for breast cancer and did
not stain normal breast tissue. To provide a more in depth
analysis of these antibodies and to further clarify the asso-
ciation of GIPC1 with different types of breast cancer, we
carefully studied 27.F7 and 27.B1 antibodies via immu-
nohistochemical analysis of breast cancer tissue. In addi-
tion, we determined that these antibodies stained the
ovarian cancer cell line SKOV-3 quite strongly and as a
result we also performed a similar analysis on serous car-
cinoma of the ovary, the most common and aggressive
type of ovarian malignancy.
Breast cancer claims the lives of many women yearly.
Recently, there have been improvements in breast cancer
treatment and survival, which has rested to a large extent
on detection and treatment of early stage disease [9-11].
Although mammography has been quite successful in
detection of breast cancer, there are still many women that
die as a result of identification of the malignancy at a late
stage [10-13]. Ovarian cancer, on the other hand, in par-
ticular epithelial carcinoma of the ovary is the leading
cause of death from gynecologic cancers in the United
States, and is the fifth leading cause of cancer death
among U.S. women. It usually occurs in women over the
age of 35, with most affected women being above the age
of 50 [14].
Approximately 5% to 10% of ovarian cancers are familial
and in most families affected with breast and ovarian can-
cer a genetic linkage has been established with the BRCA1
locus. BRCA2, is also responsible for some instances of
inherited ovarian and breast cancer [9]. Although treat-
ment modalities for ovarian cancer are lacking, survival in
most cases seems to depend on early detection and treat-
ment [14]. One of the principal reasons for such a high
mortality is the lack of effective and reliable methods for
early diagnosis of the disease [15]. Because ovarian cancer
is often asymptomatic in its early stages, most patients
have widespread disease at the time of diagnosis. Partly as
a result of this, yearly mortality in ovarian cancer is
approximately 65% of the incidence rate [16]. In addi-
tion, most diagnostic tests including manual examination
and transvaginal ultrasound cannot reliably predict early
onset of malignancy [17]. For early cancer screening phy-
sicians have relied, for the most part, on a variety of cancer
markers such as CA-125. Many of these, however, are not
reliable, as evidenced by the fallibility of CA-125 in pre-
dicting ovarian cancer, since many women with low val-
ues have malignancy [12,18].
As early detection of ovarian cancer is a key factor for long-
term survival, it is an imperative that new markers for
early onset ovarian cancer be developed. Since we identi-
fied GIPC1 as a new tumor-associated antigen that is
linked to breast cancer and that stains ovarian cancer cells
in vitro, we reasoned that it might be useful as a new
marker for these malignancies. Therefore, we extended
our studies of GIPC1 in breast and ovarian cancer to deter-
mine the utility of this cancer-associated antigen as a
marker for malignancy. In particular, a study of GIPC1
protein expression in malignant cells of ovarian tumors
might provide new avenues for the diagnosis, prognosis
and treatment of ovarian cancer, and might constitute the
basis for further study of the role that this protein might
play in malignant disease.Page 2 of 11
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Cell culture and antibodies
Human breast cancer cells MCF-7, ovarian cancer cells
SKOV3 and human primary fibroblasts were obtained
from the ATCC and maintained according to the sup-
plier's instructions. Hybridoma cell line, secreting 27.F7
and 27.B1 antibodies, were produced as a result of fusion
between the MFP-2 fusion partner cell line and human
lymphocytes derived from lymph node lymphocytes of
breast cancer patients [1]. They were maintained in 24-
well plates in RPMI 1640 media (Gibco), supplemented
with 10% Fetal Calf Serum, L-glutamine, non-essential
amino acids, pyruvate, vitamins and hypoxanthine and
thymidine (HT).
Human anti-GIPC1 monoclonal antibodies 27.B1 and
27.F7 are both IgM,κ, (Rudchenko et al., manuscript in
press BMC cancer), and were produced by growing hybri-
doma cells and used as culture media supernatant with
defined antibody concentration. For some experiments
antibodies were further purifed by gel filtration chroma-
tography on a 1 meter × 2.5 cm column packed with
Sephacryl S300 in sodium phosphate buffer (pH 7.8), 300
mM NaCl at a flow rate of 6 mL/minute. Normal goat
serum used for blocking was purchased from Sigma
(G9023). Monovalent Fab Fragment Goat Anti-Human
IgM+IgG, used for secondary blocking of light chains, was
purchased from Jackson Immunoresearch Laboratories,
Inc. (109-006044). ELISA capturing antibody, for deter-
mination of 27.B1 and 27.F7 antibody concentrations,
goat anti-human IgM, Fc-specific, was purchased from
Jackson Immunoresearch Laboratories (109007043). Per-
oxidase labeled goat anti-human IgM for ELISA was pur-
chased from Sigma (A-8400). Secondary goat anti-Human
kappa light chain FITC conjugated was purchased from
Enco Scientific Services, (2060-02), and biotinylated goat
anti-human kappa light chain, affinity purified, was pur-
chased from Vector Laboratories, Inc. (BA-3060, P1216).
Human tissues
The paraffin-embedded samples of biopsies of normal
ovaries, ovarian and breast tumor tissues were obtained
from the archives of the Institute of Pathology of Soroka
Medical Center, Israel. The research was approved by the
Institutional Ethics Committee. Classification of tumor
samples according to clinical staging, differentiation state
and tumor type was performed by the experienced pathol-
ogists from The Institute of Pathology, Soroka Medical
Center.
Cellular ELISA (cELISA)
Preparation of fixed target cells for cELISA antibody screening
Upon reaching 80–90% confluency, the target cells were
detached from the plastic dishes by incubation with
0.02% ethylenediaminetetraacetic acid (EDTA) and
0.25% trypsin for 5 min at 37°C. After a few washes with
phosphate-buffered saline (PBS) the cells were exposed to
4% formaldehyde for 15 min at room temperature and
then stored at 4°C for up to 4 weeks.
cELISA on fixed cells
Millipore suction plates were blocked with 0.3% dry milk
in PBS for 1 h at room temperature. Fixed cells were
applied to each well at 5 × 103–104 cells per well. Before
application the fixed cells were washed and resuspended
in 0.1% Tween-20/PBS (to perforate cell membranes) and
incubated for 30 min at 37°C. All the following steps were
performed in the presence of 0.3% milk in PBS. After
applying cells to the wells and washing them at least twice
by applying vacuum to the plate, antibodies were applied
to the wells and incubated with the cells for 2 h at room
temperature. Following removal of the antibodies and
subsequent washes, secondary antibodies conjugated
with HRP were applied. Conjugates used were Goat anti-
Human Ig Kappa (27.F7 and 27.B1 are IgM κ). After 30
min of incubation followed by several washings, the
orthophenylendiamine (OPD) substrate was added and
the color intensity at 492 nm was recorded.
Western blotting
Cells were lysed with freshly prepared ice cold lysis buffer
[20 mM Tris-HCl, pH 7.6, 420 mM NaCl, 0.25% NP40, 2
mM phenylmethylsulfonyl fluoride, 1 ug/ml leupeptin,
250 U/ml Trasylol (aprotinin)] and stored at -80°C or
used immediately. Protein concentration was determined
with the BioRad Protein Detection Reagent (BioRad).
Equal amounts of protein were separated on 10% SDS
polyacrylamide gels, transferred to a nitrocellulose mem-
brane and probed with relevant primary and HRP-conju-
gated secondary antibody. Membranes were processed
using an enhanced chemiluminescence kit (ECL, Amer-
sham), and visualized on Kodak BioMax MR-1 film.
Reactivity of 27.F7 and 27.B1 monoclonal antibodies 
against SK-BR-3 cell line by flow cytometry
Purified 27.B1 and 27.F7 antibodies were tested against
the representative tumor cell line to determine the reactiv-
ity by flow cytometry. Briefly, SK-BR-3 cells (0.9 × 106/300
μL) were incubated with purified antibodies (27.B1 and
27.F7) or control human myeloma IgM at 50 μg/mL for 2
hours on ice. After incubation, the cells were washed with
PBS-5% FBS and incubated with biotin-conjugated anti-
human-IgM (Pierce cat #31778, diluted 1:100) for 1 hour
on ice. The cells were washed with PBS-5% FBS, followed
by incubation with Streptavidin-Cy-Chrome (Pharmin-
gen cat# 13038A, diluted 1:120) for 30 minutes on ice.
Finally, the cells were washed and resuspended in 0.5 mL
of buffer containing propidium iodide (Molecular Probes
cat# P-1304) at 0.6 μg/mL. Tumor cell binding was deter-
mined using a FACSCalibur. Antibodies were consideredPage 3 of 11
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tive shift in fluorescence of 30% or more of the cell popu-
lation as compared to the negative control.
Immunocytofluorescence
Microscope slides were treated with 1 M hydrochloric acid
(HCl) to obtain proper cell adhesion, rinsed thoroughly
with DI water and autoclaved. The SKOV-3, MCF-7 and
SKBR-3 cell lines were trypsinized using a 0.25% trypsin
solution, transferred to the slides and incubated overnight
in growth media. After the incubation, immunofluores-
cent staining of the cells was performed, using primary
27.F7 and 27.B1 human antibodies for GIPC1 detection.
SKOV-3, SKBR-3, MCF-7 cells were stained according to
the following immunofluorescence staining protocol.
Briefly, slides were washed with PBS and blocked using
blocking solution (5% normal goat serum) (Sigma,
G9023) in PBS. After a series of washings (3 times in PBS,
5 minutes each), the slides were covered with 2 micro-
grams/ml of primary human monoclonal antibody 27.F7
or 27.B1 (IgM, k), for 1 hour at room temperature in a
humid chamber. After the incubation, the slides were
washed in PBS, blocked as above, and incubated with a
secondary anti-human kappa light chain FITC conjugated
antibodies (Enco Scientific Services, 2060-02) for 30 min-
utes. The slides were washed several times, drained,
mounted with mounting medium (Biomedia, M01) and
coverslips were applied. Cell staining was then examined
by fluorescence microscopy.
Antigen blocking
GIPC1 protein was expressed in bacteria with a 6× histi-
dine tag, purified in denatured form by NTA resin chro-
matography (Qiagen), and refolded as previously
described [19]. GIPC1 protein (15 micrograms/mL final
concentration in blocking solution) was preincubated
with 27.F7/27.B1 antibody (1.5 micrograms/mL final
concentration in blocking solution) for 1 hr at RT. Sam-
ples of breast malignant tissue and an ovarian malignant
tumor, which were previously found positive for GIPC1
staining, were utilized for this analysis. Normal ovary and
normal breast tissue served as negative controls. The stain-
ing procedure was performed according to the immuno-
histochemistry protocol outlined below, except that
instead of applying primary antibody alone a mixture of
antibody preincubated with GIPC1 protein was applied to
the slides during staining. The results were examined by
light microscopy.
Immunohistochemistry
Five μm sections were obtained from paraffin blocks.
Endogenous peroxidase activity was blocked by incuba-
tion of slides in 3% H2O2 in methanol. Following wash-
ing, tissue slides were blocked with 5% normal goat serum
in PBS. Monovalent Fab fragments of goat anti-human
IgM+IgG (Jackson Immunoresearch Laboratories, Inc.), in
blocking solution, was then applied for secondary block-
ing. The slides were washed 3 times in PBS and incubated
with primary human monoclonal antibody 27.F7 or
27.B1 in blocking solution. The slides were then washed
and incubated with a secondary antibody. The next steps
in the staining procedure were performed using
VECTASTAIN® ABC KIT (Standard) (Vector Laboratories
Inc.) according to the recommended protocol. The slides
were then incubated with the Diaminobenzidine peroxi-
dase substrate (DAB) (Sigma FAST™ 3,3 Diaminobenzi-
dine tablet sets). Mayer's Hematoxylin was applied for
nuclear counterstaining. The slides were subsequently
washed several times, drained, dehydrated, and mounted
with Eukitt® quick-hardening mounting medium and cov-
ered with coverslips. For negative controls, the primary
antibody was replaced by phosphate-buffered saline in
each set of staining.
Immunohistochemical analysis
The sections were reviewed by two pathologists (R.S.L and
B.D). Extent and intensity of staining were evaluated.
Extent assessed roughly how much of the pertinent area in
the tissue was stained and was scored as percentages: 0%,
10%, 20%, 30%, etc. up to 100% immunoreactive epithe-
lial cells. Intensity assessed the strength of staining and
was scored as 1+, weak; 2+, moderate; and 3+, strong
staining. Only moderate and strong staining, exceeding
the background staining, observed in ≥ 10% of the section
was considered positive. Such staining was not observed
in the non-neoplastic tissue in tumor sections.
Statistical analysis
Statistical analysis using Fisher one-tail and two-tail tests
for two independent samples was performed, testing the
significance of the difference between 27.B1 and 27.F7
antibodies in their ability to detect positive GIPC1 cases in
different malignant and benign tumors of the ovary and
breast. This test was also used to make comparisons
between different tumors with respect to the frequency of
positive cases detected by these antibodies. The P value
indicates significance at a value of < 0.05.
Results
Fully human monoclonal antibodies 27.B1 and 27.F7 
detect GIPC1 in different cancer cell lines in a highly 
specific manner
We previously described the construction of a unique
fusion partner cell line, MFP-2, and its use for the immor-
talization of both human peripheral blood and lymph
node B-lymphocytes [1]. We have also demonstrated that
MFP-2 was employed for the isolation of a panel of autol-
ogous breast cancer specific antibodies from breast cancer
patients [20]. Two of these native fully human mono-
clonal antibodies (fhMAbs), designated 27.B1 and 27.F7,Page 4 of 11
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patient, whose target is the PDZ domain-containing pro-
tein known as GIPC1, were chosen for further study. We
previously determined that this protein is specifically up-
regulated in malignant breast epithelial tissue/cells and in
breast cancer cell lines, is not detected in normal breast
epithelia, and the cytosol/membrane localization of the
target antigen is especially strong (Rudchenko et al., man-
uscript in press BMC cancer).
The question that arises based on our previous results
described above is whether fhMAbs 27.B1 and 27.F7 react
specifically with breast cancer only, or this reaction is
characteristic of other neoplasias. To investigate this, we
tested the 27.F7 and 27.B1 antibodies using cELISA, West-
ern blot analysis and immunocytofluorescent staining on
several other cell lines, including the already examined
MCF-7 breast cancer cell line and the additional cell line
SKOV-3 (ovarian carcinoma), thus expanding the analysis
to other cell types, using WS1 (human primary fibrob-
lasts) as a negative control. The results have revealed that
both 27.B1 and 27.F7 antibodies demonstrate positive
immunoreactivity against breast (MCF7) and ovarian
(SKOV3) cancer cell lines (Figure 1). Immunofluorescent
analysis demonstrated an apparent diffuse cytoplasmic
staining of MCF-7 and SKOV-3 cancer cells, whereas
human fibroblasts had no detectable staining (Data not
shown).
Fully human monoclonal antibodies 27.F7, 27.B1 react 
with the cell surface of SKBR-3
To evaluate the relative affinity of the 27.F7 and 27.B1
human monoclonal antibodies to breast cancer cells we
employed flow cytometry with live SKBR-3 cells. The
results showed that both 27.B1 and 27.F7 antibodies
demonstrate positive cell-surface reactivity against the
breast cancer cell line, SKBR-3. The antibody 27.F7 dem-
onstrated strong reactivity with an 8.5-fold increase in
median fluorescence (MF) above the negative control
(myeloma IgM), whereas antibody 27.B1 displayed a
lower median fluorescence with a 3.7-fold increase in MF
over the negative control. Representative flow histograms
are shown in Figure 2. These results demonstrate that
these two antibodies display a differential binding pattern
to GIPC1 antigen in live cancer cells.
Internalization of 27.B1 and 27.F7 monoclonal antibodies 
into breast cancer cells
Following the results demonstrated positive cell-surface
reactivity of both 27.B1 and 27.F7 antibodies against the
breast cancer cell line, SKBR-3, we tried to determine if the
cell-surface bound antibodies were internalized into
MCF7 cells rather than shed from the plasma membrane.
To this end, antibody-treated live cells were further evalu-
ated for intracellular staining by confocal microscopy. The
results demonstrated that both 27.B1 (Figure 3B) and
27.F7 (Figure 3C) antibodies demonstrated positive intra-
cellular staining of MCF7 breast cancer cell line. In con-
trast, clear intracellular staining was not visualized with
the non-internalizing control antibody (human myeloma
IgM) (Figure 3A).
27.B1 and 27.F7 monoclonal antibodies specifically bind 
GIPC1 antigen in paraffin-embedded tissue samples
To confirm the specificity of 27.F7 and 27.B1 antibodies
to the native GIPC1 protein, we performed an antigen
blocking experiment. For this purpose, 27.F7 and 27.B1
antibodies were incubated with a high concentration of
bacterial expressed and refolded GIPC1 antigen [19] prior
to application on tissues, and then the standard protocol
(see Materials and Methods) for immunohistochemical
Immunoreactivity of human monoclonal antibodies (hMAbs) 27.B1 and 27.F7 against different cancer cell linesFigure 1
Immunoreactivity of human monoclonal antibodies 
(hMAbs) 27.B1 and 27.F7 against different cancer cell 
lines. A, cELISA: The binding index is the normalized anti-
body binding relative to the background antibody reactivity 
with primary human fibroblasts. Both hMAbs 27.B1 and 27.F7 
display an increased binding to formalin-fixed breast (MCF7) 
and ovarian (SKOV3) cancer cell lines in comparison to nor-
mal fibroblasts (WS1). B, and C, Western blot analysis: The 
target antigen, GIPC1, for monoclonal 27.B1 (B) and 27.F7 
(C) in MCF7 and SKOV3 cancer cell lines was identified by 
Western blot. The target antigen is present in MCF7 (breast) 
and SKOV3 (ovarian) cell lines but is not detected in WS1 
(normal fibroblasts). β-Actin served as the loading control.
A. 
            
B.                                                                                C. Page 5 of 11
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mens from a paraffin-embedded tissue block that were
previously stained with these antibodies and identified as
positive. Following an antibody-blocking procedure for
endogenous immunoglobulins in the tissue, the speci-
mens were examined by light microscopy, and no staining
was detected: 27.B1 and 27.F7 antibodies were both
blocked completely following the addition of exogenous
GIPC1 antigen whereas addition of extraneous protein,
such as lysozyme, did not block antibody staining (data
not shown). This confirmed the specificity of these anti-
bodies to the GIPC1 antigen in the tissue sections. These
results demonstrate that monoclonal antibodies 27.B1
and 27.F7 target endogenous GIPC1 protein specifically,
Reactivity of 27.B1 (A) and 27.F7 (B) against SK-BR-3Figure 2
Reactivity of 27.B1 (A) and 27.F7 (B) against SK-BR-3. Fluorescence intensity of tumor cells incubated with myeloma 
IgM (1), 27.B1 (A-2), and 27.F7 (B-2) demonstrate positive cell-surface reactivity against the breast carcinoma cell line, SK-BR-
3.
BA
Internalization of 27.B1 and 27.F7 antibodies into breast cancer cellsFigure 3
Internalization of 27.B1 and 27.F7 antibodies into breast cancer cells. 27.B1(B) and 27.F7 (C) antibodies were inter-
nalized into MCF7 cells. Antibody-treated cells were evaluated for intracellular staining with the aid of laser scanning confocal 
microscopy. Warming of the antibody-bound cells to 37°C for 30 minutes revealed intracellular staining of the MCF7 breast 
cancer cell line. In contrast, no intracellular staining was visualized with the non-internalizing control antibody (human myeloma 
IgM).
MCF7
IgM   27.B1 27.F7 
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lular expression level of the GIPC1 protein.
Human monoclonal antibodies 27.B1 and 27.F7 identify 
elevated GIPC1 protein levels in breast cancer with 
differential staining patterns that correlate with tumor 
invasiveness
Following the results obtained with different cancer cell
lines, we have extended our study by further analysis of
27.B1 and 27.F7 antibodies interaction with different
types of malignant and benign breast tumors in order to
evaluate the incidence of GIPC1 enhanced expression
within a given tumor type and to compare GIPC1 expres-
sion in different breast tumor types. Different breast tis-
sues including two benign entities – fibroadenoma and
hyperplasia of the breast, and four malignant tumors –
lobular carcinoma in situ, ductal carcinoma in situ, inva-
sive lobular carcinoma and invasive ductal carcinoma
(invasive and metastatic type) were examined. Immuno-
reactivity of 27.B1 and 27.F7 antibodies was observed
only in invasive ductal (IDC) and invasive lobular carci-
noma (ILC) (Figure 4-A and Table 1), in contrast to hyper-
plasia, fibroadenoma, lobular carcinoma in situ (LCIS)
and ductal carcinoma in situ (DCIS) that demonstrated no
staining at all (Table 1).
According to our findings (Table 1), 27.B1 displays a rela-
tively higher reactivity with breast tumors, detecting a
greater percentage of cases upon the examination of each
tumor type. In contrast, 27.F7 displays a lower reactivity,
staining a lower percentage of tumor cells in the positive
cases. Statistical examination of invasive ductal carcinoma
(IDC) demonstrated significant difference between these
antibodies (p < 0.001). Noteworthy, both antibodies did
not stain benign tumors of the breast, nor normal con-
trols. The 27.F7 and 27.B1 antibodies both display differ-
ential staining between various tumor types. Interestingly,
GIPC1 staining with both 27.F7 and 27.B1 antibodies was
positive in invasive breast cancer but not in in-situ carci-
nomas (p < 0.001).
Following the experiments with breast cancer, we decided
to evaluate the possible association of 27.B1 and 27.F7
antibody staining with ovarian cancer tissue obtained
from patients with benign cystadenoma, borderline
tumor and the most aggressive ovarian malignancy-serous
carcinoma of the ovary.
27.F7 and 27.B1 antibodies detect GIPC1 in ovarian serous 
carcinoma and shows differential staining of borderline 
tumors
Three types of ovarian tumors were examined using nor-
mal ovarian tissue as a negative control. Benign ovarian
serous cystadenoma, serous cystadenoma of uncertain
malignant potential (borderline malignancy) and the
overtly malignant ovarian serous adenocarcinoma were
all examined using the same immunohistochemical tech-
nique. The results demonstrate different staining for 27.F7
and 27.B1 antibodies in normal, benign and malignant
ovarian epithelium. These antibodies also revealed differ-
ential staining of borderline tumors, displaying different
percentage of positive cases, compared to benign and
malignant tumors. Noteworthy, a correlation between
positive staining and tumor invasiveness was observed
(Table 2), which is similar to the breast cases. This implies
a difference in GIPC1 over-expression between benign
and malignant tumors, independent of the tissue type.
The percentage of positive cases for 27.B1 antibodies cor-
related with increasing malignancy of the ovarian tumors.
Overall, a similar correlation was observed for the 27.F7
antibody as well, although it was negative in the border-
line tumors.
According to our findings, 27.F7 and 27.B1 antibodies
recognize ovarian cancer specifically, revealing the highest
number of positive cases (more than 50%) in serous car-
cinoma (Table 2). On the other hand, the normal control
remains negative, indicating a very high specificity of
these antibodies to the malignant tumor. Both antibodies
demonstrated similar reactivity with the malignant serous
carcinoma, and thus, similar ability to detect elevated lev-
els of GIPC1 protein in this type of ovarian tumor. Figure
4-B illustrates immunohistochemical staining of ovarian
tumors using 27.F7 and 27.B1 antibodies.
Examination of borderline ovarian tumors (proliferative
epithelial tumors with low risk of recurrence and metas-
tases) showed that only 27.B1 antibody was reactive
against this type of tumor, while 27.F7 was completely
negative (Table 2). This difference was statistically signifi-
cant (p < 0.045). According to these findings, 27.B1 and
27.F7 antibodies display differential staining of border-
line tumors, suggesting different epitope recognition on
the GIPC1 antigen, which is in agreement with previous
results (Rudchenko et. al., Manuscript in press BMC can-
cer). The percentage of positive cases found in benign and
borderline tumors is also lower than in overtly malignant
serous carcinoma, suggesting a lower incidence of
enhanced GIPC1 expression in these tumor types. How-
ever, only the increased immunoreactivity for 27.F7 anti-
body in malignant tumors compared to borderline
tumors was statistically significant (p = 0.007).
All of the above findings suggest the next logical step in
this study: identification of a correlation between positive
tissue staining (high incidence of enhanced expression of
GIPC1 in malignant tumors) and cancer specific autoanti-
body levels in ovarian and breast patients' sera targeting
the GIPC1 antigen. According to this working hypothesis,
the detection of these circulating anti-cancer specific anti-Page 7 of 11
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Immunohistochemistry of ovarian and breast tissuesFigure 4
Immunohistochemistry of ovarian and breast tissues. 4-A Immunohistochemistry of breast tumor tissue using 27.B1 
(A, B, C) and 27.F7 (D, E, F) antibodies. Hyperplasia (A, D) and ductal carcinoma in situ (B, E) are negative, and invasive ductal 
carcinoma (C, F) is positive (Original magnification ×200). Black arrows indicate negative stained regions and red arrows indi-
cate positive stained regions. 4-B Immunohistochemistry of ovarian tissue using 27.B1 (A, B, C) and 27.F7 (D, E, F) antibodies. 
Normal ovary: the epithelial monolayer is negative (A, D) (magnification ×400), borderline tumors (B, E) (magnification ×200) 
show different staining (27.B1 – positive, 27.F7 – negative). Epithelial serous carcinoma (C, F) is positive for both antibodies 
(magnification ×400). Black arrows indicate the negative staining and red arrows indicate the positive staining of the epithelium.
BMC Cancer 2008, 8:247 http://www.biomedcentral.com/1471-2407/8/247bodies using the cancer-associated GIPC1 antigen might
be a sensitive marker for certain early stage malignancies
and superior to methodologies based on cancer-associ-
ated antigen detection. As a result, our next goal is the
development of a novel screening technique based on
sensitive detection of cancer specific autoantibodies in
patients' sera instead of searching for circulating tumor
antigen, which is more commonly performed in conven-
tional screening techniques today.
Discussion
In this pilot study we determined that the reactivity of
fully human monoclonal antibodies (fhMAbs) 27.B1 and
27.F7, derived from lymph node B-cells of a breast cancer
patient and targeting the PDZ domain-containing protein
known as GIPC1, are specific to breast and ovarian cancer.
Through exploration of the interaction of 27.F7 and 27.B1
autoantibodies with breast cancer cell lines SKBR-3, MCF-
7 and ovarian cancer cell line SKOV-3, we found a very
strong signal in staining of breast, ovarian and pancreas
cancer cell lines, but not in normal controls. The results of
these experiments reveal that these two anti-GIPC1
human monoclonal antibodies bind to cancer cells specif-
ically but are not limited to binding a single malignant
cell type. Instead they have broader cancer reactivity than
we previously thought. Moreover, flow cytometry has
demonstrated that the reactivity of 27.F7 antibody with
the SKBR-3 cell surface is significantly stronger than that
of 27.B1. Furthermore, we have also demonstrated that
these antibodies not only bind to the surface of cancer
cells, but are internalized, in contrast to control immu-
noglobulin. As such, these antibodies may impact directly
on GIPC1 intracellularly, and therefore may affect a vari-
ety of different cancer-associated signaling pathways.
Therefore, these antibodies may be useful not only diag-
nostically but also therapeutically in the future.
These results provided the impetus for our present immu-
nohistochemical studies, and further examination of
27.B1 and 27.F7 human monoclonal antibodies can pro-
vide a base for their potential future applications in
immunohistochemical research, cancer screening and
diagnostics.
We also studied the interactions of 27.F7 and 27.B1 anti-
bodies with human breast and ovarian tumor tissue under
the working hypothesis that these two human mono-
clonal antibodies target different GIPC1 epitopes. The
immunohistochemical studies of 27.F7 and 27.B1 have
also enabled a comparison of GIPC1 levels in different
types of breast and ovarian tumors. Our results clearly
demonstrate elevated levels of GIPC1 in malignant, but
not benign breast tumors. Therefore, we suppose that this
protein is cancer-associated, and might play a role in a
cancer-associated process. Another potential explanation
that might be suggested is that malignant processes taking
place in the proliferating cells require an increased
amount of GIPC1 protein, enabling its detection in
immunohistochemical staining.
Analysis of ovarian tumors with 27.F7 and 27.B1 antibod-
ies demonstrated differential staining between them,
which was statistically significant for borderline ovarian
tumors, displaying exclusive binding of 27.B1, but not
27.F7 antibody.
Based on all of our immunohistochemical findings we
hypothesize that the antibodies target different epitopes.
This is also supported by the fact that they display differ-
ential binding upon examination of invasive malignant
tumors, and also with respect to borderline ovarian
tumors. Since our immunohistochemical results were
obtained in a pilot study, this finding requires further
investigation on a larger sampling to clarify if this might
be used as cancer diagnostic and prognostic tool.
Benign, borderline and malignant conditions are different
in terms of their gross morphology and fine structure and
Table 1: IHC staining results for 27.B1 and 27.F7 in various 
breast lesions.




LCIS (Lobular carcinoma in situ) 0/4 0/4
DCIS (Ductal carcinoma in situ) 0/4 0/4
ILS (Invasive lobular carcinoma) 9/10 (90%) 8/15 (53%)
IDC (Invasive ductal carcinoma) 24/25 (96%) 11/23 (48%)
Table 1 summarizes the results obtained from the 
immunohistochemistry of the breast lesions and illustrates the 
difference in staining percentage (positive cases out of the total 
number of samples studied) between different tumor types, implying 
differential incidence of GIPC1 enhanced expression.
Table 2: IHC staining results for 27.B1 and 27.F7 in various 
ovarian tissues.
Tumor type Positive cases/total cases
27.B1 27.F7
Normal ovary 0/8 0/8
Benign serous cystadenoma 2/15 (14%) 3/15 (21%)
Serous borderline tumor 4/11 (36%) 0/11
ESC (Epithelial serous carcinoma) 7/13 (54%) 8/15 (53%)
Difference between the number of GIPC-positive cases detected by 
27.B1 and 27.F7 antibodies was significant (p < 0.045) in borderline 
tumor only. Table 2 summarizes the results obtained from the 
immunohistochemistry of the ovarian tissues and illustrates the 
difference in staining percentage (positive cases out of the total 
number of samples studied) between different tissues, implying 
differential incidence of GIPC1 enhanced expression.Page 9 of 11
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BMC Cancer 2008, 8:247 http://www.biomedcentral.com/1471-2407/8/247are expected to be associated with different cellular proc-
esses, perhaps leading to different protein distribution
and compartmentalization. The conformation of a cellu-
lar protein might also change according to its function at
a given moment and in a given tissue implying different
epitope accessibility, which might explain in part the dif-
ferential staining obtained by 27.B1 and 27.F7 antibodies.
Nonetheless, the reason for such a difference between the
sensitivities of these antibodies to the GIPC1 protein in
the tissues that were examined still remains unclear.
Recently, it has been shown that GIPC1 can form multim-
ers by binding to itself and that the PDZ domain is
involved in the GIPC-GIPC interaction. Furthermore, it
was shown that whereas the bulk of cytosolic GIPC1 was
present as monomer, GIPC1 homotrimer was readily
detectable in the membrane fraction [21]. These results
support our findings and help explain the differential tis-
sue staining obtained by 27.B1 and 27.F7 antibodies.
The results obtained from the examination of benign
ovarian cystadenoma, borderline ovarian tumor and inva-
sive ovarian serous carcinoma demonstrate a direct corre-
lation between tumor malignancy and staining. It can be
clearly seen that the highest number of GIPC1 positive
cases was found for epithelial serous carcinoma – a malig-
nant tumor of the ovary. The behaviour of borderline
ovarian tumors is uncertain; they usually behave in a
benign fashion, but they have a potential for recurrences
in the form of peritoneal implants or even as a metastatic
disease. With this in mind, along with other results, we
developed a few hypotheses regarding the possible cause
for significantly elevated levels of GIPC1 detected in
malignant and borderline ovarian tumors. We propose
that GIPC1 overproduction is not a direct cause of cancer,
as mentioned above, but is rather a byproduct of the cel-
lular response to the transformed state. In addition, it
could be evidence for an attempt by the cell to balance
and regulate itself.
Regardless of the role that GIPC1 might play in carcino-
genesis, it is clearly a novel cancer-associated antigen, sug-
gesting that further research should be conducted in order
to define its role in cell transformation and cancer devel-
opment. To further support the correlation between
GIPC1 expression and clinical pathologies, a full-scale
study is being performed. Our study, however, forms the
basis for further broad-based research of the differential
interaction of the fully human 27.B1 and 27.F7 autoanti-
bodies with GIPC1 antigen in different malignant and
benign tumors, which will likely be useful for research
and diagnostics. Further investigations of the role these
antibodies play in the progression of cancer, and the role
of GIPC in cancer, is therefore warranted.
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